You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK (GenomeWeb News) – Danaher reduced its commitments on a credit facility to $1 billion, the conglomerate disclosed after the close of the market on Wednesday.
The company said it had borrowed $455 million under the new credit agreement, of which $435 million was used to pay the outstanding amounts from a previous agreement.
In an SEC document, Danaher disclosed it also has reduced its commitments on a 364-day credit facility it entered into in connection with its purchase of Beckman Coulter, while it terminated another existing credit facility.
The company has entered a bridge credit agreement for $2 billion and a revolving credit agreement for up to $1 billion.
The credit facility consists of a term loan of up to $20 million and a $10 million revolving line of credit, which will be used to purchase capital equipment and expand laboratory capacity.
The molecular diagnostics firm intends to pursue additional disease targets with its AlloMap technology.
The firm signed an agreement for a $15 million credit line and term loans totaling $6 million.
The firm has signed a $500 million credit facility, which it said will be used to provide working capital and fund general corporate purposes.
The firm said there is currently $240 million of borrowings outstanding under the credit facility.
Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.
The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.
Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.
In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.